Core Viewpoint - Neogen Corporation is facing a class action lawsuit due to alleged violations of the Securities Exchange Act of 1934, with claims that the company and its executives misled investors regarding the integration of its business with 3M's Food Safety Division and the financial implications of this merger [1][3][4]. Company Overview - Neogen Corporation specializes in the development, manufacture, and marketing of products and services focused on food and animal safety [2]. Class Action Details - The class action lawsuit is titled "Operating Engineers Construction Industry and Miscellaneous Pension Fund v. Neogen Corporation" and allows investors who purchased Neogen common stock between January 5, 2023, and June 3, 2025, to seek appointment as lead plaintiff by September 16, 2025 [1][7]. - The lawsuit alleges that Neogen's executives made false statements about the progress of the integration with 3M and downplayed inefficiencies that arose during this process [3][4]. Financial Performance - On January 10, 2025, Neogen reported a significant GAAP net income loss due to a $461 million non-cash goodwill impairment charge related to the 3M acquisition, alongside a reduction in fiscal year 2025 revenue and EBITDA guidance [4]. - In the third quarter of 2025, Neogen reported a loss of $11 million, a significant increase from a $2 million loss the previous year, with revenue declining by 3.4% to $221 million due to integration issues [5]. - On June 4, 2025, Neogen projected an EBITDA margin drop to the high teens from 22%, attributing this to elevated inventory write-offs, which led to a further decline in stock price by over 17% [6].

Core Viewpoint - A class action lawsuit has been filed against Fiserv, Inc. for alleged violations of federal securities laws, focusing on misleading statements and operational issues related to its Payeezy and Clover platforms [1][2][3]. Group 1: Lawsuit Details - The lawsuit seeks damages for investors who purchased Fiserv securities between July 24, 2024, and July 22, 2025, inclusive [2]. - Allegations include that Fiserv forced Payeezy merchants to transition to Clover due to cost-related issues, leading to inflated revenue growth figures for Clover [3]. - It is claimed that many former Payeezy merchants abandoned Clover for competitors due to high pricing and poor customer service, resulting in a deceleration of Clover's growth [3]. Group 2: Next Steps for Investors - Investors who suffered losses in Fiserv have until September 22, 2025, to request appointment as lead plaintiff in the class action [4]. - The law firm representing the investors operates on a contingency fee basis, meaning they only collect fees if the case is successful [5]. Group 3: Law Firm Background - Bronstein, Gewirtz & Grossman, LLC is a nationally recognized law firm specializing in securities fraud class actions and has recovered hundreds of millions for investors [6].

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices involving Harrow, Inc. and its officers or directors [1] Financial Performance - Harrow reported Q1 2025 revenue of $47.8 million, which was below the consensus estimate of $57.0 million [3] - The company also reported an adjusted EBITDA of -$1.9 million, missing the expected $11.9 million [3] - Following the financial results announcement, Harrow's stock price decreased by $1.00 per share, or 4.07%, closing at $23.59 per share on May 8, 2025 [3]

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices involving American Outdoor Brands, Inc. and its officers or directors [1] Financial Performance - On June 26, 2025, American Outdoor reported its financial results for Q4 and the full fiscal year 2025, revealing that retailers accelerated orders, pulling forward an estimated $8 million to $10 million in sales from the upcoming fiscal year [3] - The company announced the suspension of its fiscal 2026 guidance due to uncertainties surrounding tariffs [3] Stock Market Reaction - Following the financial results announcement, American Outdoor's stock price dropped by $1.57 per share, or 13.13%, closing at $10.39 per share on June 27, 2025 [4]

Core Viewpoint - Pomerantz LLP is investigating claims related to potential securities fraud or unlawful business practices involving Necessity Retail REIT, Inc. following its acquisition by Global Net Lease, Inc. [1][2] Group 1: Investigation Details - The investigation focuses on whether Necessity Retail and certain officers or directors engaged in securities fraud or other unlawful business practices [2] - Investors who received shares of Global Net Lease in connection with the merger on September 12, 2023, are encouraged to contact Pomerantz LLP [1] Group 2: Financial Projections and Market Performance - The Offering Materials for the merger projected Adjusted Funds From Operations (AFFO) for the combined company to be $399.8 million for 2024 and $409.0 million for 2025 [4] - Since the merger date, Global Net Lease's share price has declined by over 33% [4]

Core Viewpoint - MarineMax, Inc. is under investigation for potential securities fraud and unlawful business practices following a significant reduction in profit guidance and a sharp decline in stock price [1][3][4]. Financial Performance - On July 24, 2025, MarineMax reported its financial results for Q3 2025, cutting its profit guidance by 50% at the midpoint to a range of $0.45 to $0.95 per share, down from a previous guidance of $1.40 to $2.40 per share [3]. - The CEO attributed the weak retail demand in the recreational marine industry to ongoing economic uncertainty, evolving trade policies, and geopolitical tensions, leading consumers to delay purchases [3]. Stock Market Reaction - Following the announcement of the reduced profit guidance, MarineMax's stock price fell by $4.61, or 16.87%, closing at $22.71 per share on July 24, 2025 [4].

NEW YORK, July 28, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Geely Automobile Holdings Limited ("Geely" or the "Company") (OTCMKTS: GELYF; GELYY). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Geely and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. On this news, the value of Geely securities fell sharpl ...

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices by Dow Inc. and its officers or directors, following a significant drop in the company's stock price after disappointing financial results for Q2 2025 [1][3]. Financial Performance - Dow reported net sales of $10.1 billion for Q2 2025, which represents a 7% decrease year-over-year and a 3% decline sequentially [3]. - The decline in net sales was attributed to decreases across all operating segments, despite seasonally higher demand in Performance Materials & Coatings [3]. - Following the financial results announcement, Dow's stock price fell by $5.30 per share, or 17.45%, closing at $25.07 per share on July 24, 2025 [3]. Corporate Actions - Dow's CEO announced an adjustment to the company's dividend to maintain a balanced capital allocation framework [3].

Core Viewpoint - A class action lawsuit has been filed against Fiserv, Inc. for alleged violations of securities laws, claiming the company made false and misleading statements regarding its Clover platform and its impact on revenue growth [1][4]. Group 1: Lawsuit Details - The lawsuit is based on violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 [1]. - Investors who purchased Fiserv securities between July 24, 2024, and July 22, 2025, are encouraged to participate in the lawsuit before the deadline of September 22, 2025 [2]. - The class has not yet been certified, meaning potential participants are not currently represented by an attorney [3]. Group 2: Allegations Against Fiserv - The complaint alleges that Fiserv misled the market by forcing merchants to migrate from its Payeezy platform to the Clover program due to cost issues, which artificially inflated Clover's revenue growth [4]. - The company reportedly lost customers to competitors because of Clover's high prices and poor customer service, indicating that public statements made by Fiserv were materially misleading [4]. - As a result of these misleading statements, investors suffered damages when the truth about Fiserv's business practices was revealed [4].

Core Viewpoint - A lawsuit has been filed against Replimune Group, Inc. and its senior executives for potential violations of federal securities laws, following a significant decline in stock price after the FDA's response regarding the company's lead product candidate RP1 [1][2][5]. Group 1: Company Overview - Replimune is a clinical-stage biotechnology company focused on developing oncolytic immunotherapies for cancer treatment, with its lead product candidate being RP1 for melanoma [3]. - The company announced positive results from its IGNYTE Phase 1/2 clinical trial for RP1 in combination with nivolumab on June 6, 2024, and subsequently submitted a biologics license application (BLA) to the FDA based on these results [3]. Group 2: Legal Issues - The lawsuit claims violations under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934, representing investors who purchased Replimune securities [2]. - The complaint alleges that the IGNYTE Phase 1/2 trial design was inadequate to produce reliable results, despite the company promoting its outcomes [4]. Group 3: Stock Performance - Following the FDA's Complete Response Letter on July 22, 2025, which indicated that the IGNYTE trial was not considered adequate for substantial evidence of effectiveness, Replimune's stock price fell by more than 75% [5].